TECVAYLI + DARZALEX FASPRO FDA Approval: What Pharma Executives Need to Know
On March 5, 2026, the U.S. Food and Drug Administration (FDA) approved the combination of TECVAYLI® (teclistamab-cqyv) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. The approval, granted to Johnson & Johnson (NYSE: JNJ), marks a landmark shift in the RRMM treatment landscape — extending the reach of bispecific antibody therapy to as early as the second line of treatment.
TECVAYLI, a first-in-class BCMA-directed bispecific T-cell engager, works synergistically with DARZALEX FASPRO, a CD38-directed subcutaneous monoclonal antibody, to prime and activate the immune system against myeloma cells expressing the BCMA protein. This approval also marks the first-ever regulatory clearance of a bispecific antibody in combination with a CD38-directed therapy for RRMM, a development that signals a new era of immune-oncology combinations in hematology.
The FDA selected the teclistamab supplemental Biologics License Application (sBLA) for the Commissioner’s National Priority Voucher (CNPV) Pilot Program, in addition to granting Breakthrough Therapy Designation and Real-Time Oncology Review — underscoring the clinical urgency and commercial significance of this approval.
Gain in-depth analysis of the Multiple Myeloma market size, competitive dynamics, emerging therapies, and pipeline intelligence for the multiple myeloma market. Download DelveInsight’s Multiple Myeloma Market Report.
MajesTEC-3 Clinical Results: Unprecedented Efficacy Data
The approval is anchored in data from the ongoing Phase 3 MajesTEC-3 randomized study, which evaluated teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone combined with either pomalidomide or bortezomib (DPd/DVd) in RRMM patients with at least one prior line of therapy. After a median follow-up of three years, the results — simultaneously published in The New England Journal of Medicine and presented as a late-breaking oral at the 2025 ASH Annual Meeting — delivered outcomes that no prior bispecific antibody trial has achieved:
-
Risk Reduction in Progression or Death (HR): 0.17 — an 83% reduction vs. standard of care (95% CI: 0.12–0.23; P<0.0001)
-
3-Year Progression-Free Survival (PFS) Rate: 83% (TECVAYLI® + DARZALEX FASPRO®) vs. 30% (control arm)
-
3-Year Overall Survival (OS) Rate: 83.3% vs. 65.0% (HR 0.46; 95% CI: 0.32–0.65; P<0.0001)
-
Overall Response Rate (ORR): 89.0% vs. 75.3%
-
Complete Response or Better (≥CR): 81.8% vs. 32.1%
-
MRD-Negativity Rate: 58.4% vs. 17.1%
From a safety standpoint, the combination demonstrated a manageable and well-characterized profile. Grade 3/4 treatment-emergent adverse events were comparable between arms (95.1% vs. 96.6%), largely driven by cytopenias and infections. Cytokine release syndrome (CRS) occurred in 60.1% of patients; all cases were Grade 1/2, none led to treatment discontinuation, and rates of high-grade infections declined after the first six months following established prophylaxis protocols. Immune effector cell-associated neurotoxicity syndrome (ICANS) was rare at 1.1%. Treatment discontinuation due to adverse events was low at 4.6%.
These data represent the first Phase 3 confirmation of a bispecific antibody combination in Relapsed/Refractory Multiple Myeloma and are expected to fundamentally recalibrate competitive strategies across the multiple myeloma treatment space.
Benchmark TECVAYLI® + DARZALEX FASPRO® against competing bispecific antibodies, CAR-T therapies, and next-generation BCMA-directed assets in DelveInsight’s comprehensive Multiple Myeloma pipeline tracker.
Multiple Myeloma Market and Commercial Implications
Multiple myeloma is the third most common blood cancer globally and remains an incurable disease. In the United States alone, more than 35,000 new cases were estimated in 2024, with over 12,000 deaths. Despite significant therapeutic advances over the past decade, driven largely by proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, and, more recently, BCMA-directed therapies, approximately 40% of patients experience disease relapse after initial treatment, representing a persistent and commercially significant unmet need.
This approval fundamentally alters the competitive landscape. The extension of TECVAYLI® + DARZALEX FASPRO® to the second-line setting positions Johnson & Johnson to capture a significantly larger patient population than its prior fourth-line indication allowed. For pharma executives, the implications span portfolio strategy, market access planning, payer negotiations, and competitive benchmarking across all RRMM-directed assets — from established CD38 regimens to late-stage bispecifics and CAR-T cell therapies.
The combination’s subcutaneous administration, steroid-sparing approach, and community-practice compatibility further differentiate it from competing regimens requiring more complex infusion infrastructure, potentially accelerating adoption across diverse care settings.
DelveInsight’s Multiple Myeloma market report covers market sizing, epidemiology forecasts, revenue projections, and commercial opportunity analysis through 2034.
Strategic Significance for the Oncology Industry
The MajesTEC-3 approval arrives at a pivotal moment for the oncology bispecific antibody class. As of early 2026, several BCMA- and GPRC5D-directed bispecifics are either approved or in late-stage development, intensifying competition for earlier lines of myeloma therapy. Johnson & Johnson’s success in securing second-line approval, backed by Phase 3 OS data, a rarity in this indication, raises the evidentiary bar for competitors and will likely influence ongoing regulatory negotiations, payer reimbursement frameworks, and clinical guideline updates across key markets.
For business development, licensing, and corporate strategy teams, the approval also highlights the commercial value of rational combination strategies pairing bispecific T-cell engagers with established backbone therapies, a template that other developers across myeloma and beyond are actively evaluating.
DelveInsight’s experts provide bespoke consulting engagements for pharma strategy, competitive benchmarking, licensing due diligence, and portfolio gap analysis in the multiple myeloma space. Request a Multiple Myeloma Custom Competitive Intelligence
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services